Use of Oxaliplatin for Enhancing Radiosensitivity in Radiotherapy of Cervical Cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 26, 2009
app pub date -
Sep 26, 2007
filing date -
Sep 26, 2007
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to a method for enhancing radiosensitivity in radiotherapy of cervical cancer by administering to cervical cancer cells an effective amount of oxaliplatin. Radiation combined with pretreatment of oxaliplatin according to the present invention helps to enhance the cytotoxicity of radiation and result in augmenting radiation-induced mitotic catastrophe. The analysis on molecular mechanism revealed that oxaliplatin augmented the radiation-induced DNA double-strand break indicated by reducing gamma-H2AX expression, abrogated radiation-induced ATM phosphorylation and reduced the Chk2 phosphorylation. Oxaliplatin can be used as a promising radiosensitizer for treatment of cervical cancer in radiotherapy.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully